A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
Status:
Completed
Trial end date:
2011-08-02
Target enrollment:
Participant gender:
Summary
Approximately 40 healthy subjects will be enrolled. Each subject will participate in the
study for approximately 9 weeks. There will be four treatment sequences with a 5-7 day
washout between treatments. Subjects will be admitted to the clinical unit on Day-1 of each
dosing period and will remain in the unit until Day 2. Each subject will receive a single
dose of each of the four treatments on Day 1 of each treatment period in a randomized
fashion. Subjects will be discharged from the clinical research unit after the completion of
all assessments on Day 2 of each period and return approximately 5-7 days later for the next
dose period. Serial pharmacokinetic samples will be collected for up to 24 hours following
each treatment.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination Zanamivir